Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTBEAM-01A sub-study of zilovertamab vedotin in pediatric and young adult relapsed/refractory cancers
MOH_2024-04-15_013375Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zilovertamab vedotin in B cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) and 2 more, sponsored by Merck & Co. Started Feb 2024; status: recruiting.
02
Drugs
zilovertamab vedotin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)diffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)neuroblastomaEwing sarcoma
Beyond the preview
Go deeper on MOH_2024-04-15_013375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-04-15_013375.